 |
|
|
| |
LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/r-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Lois Larsen , Thomas Podsadecki, Tami Pilot-Matias, and Christine Collins - Research and Development, AbbVie Inc.
|
| |
|
|
|
|
|
